Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Early-Onset Familial AD: Research
Where to Turn for Research: Human Studies of eFAD


Posted 2 October 2007

Important Notice: Alzheimer Research Forum does not provide medical advice nor promote any product or service. The contents are for informational purposes only and are not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on this web site. The views of individuals quoted on this site are not necessarily those of the Alzheimer Research Forum.

Washington University, St. Louis, Missouri

Summary
The Familial Adult Children Study (FACS) is an observational study to observe the presymptomatic stages of disease development. It invites all adult volunteers in families who have an autosomal-dominant inheritance pattern of AD, i.e., disease in one parent passed on at 50 percent risk. This typically, but not always, means an early onset. Families in whom a mutation is identified can enter the FACS study. Those in whom a mutation can't be found right away are also welcome at WashU; they can enter a FAD genetics study led by Dr. Alison Goate until their gene is found. Then they can enter the FACS study.

Study Leaders/Contacts
Randall Bateman, M.D.
Website: http://www.neuro.wustl.edu/people/bateman.html
E-mail: batemanr@neuro.wustl.edu
Website: http://facs.wustl.edu
Website: http://alzheimer.wustl.edu
Paging Operator: 314-362-1242
Clinic Phone: 314-286-1967

Research Contact: Wendy Sigurdson, RN
Phone: 314-362-2256
Fax: 314-362-2244
Washington University School of Medicine
660 South Euclid
Campus Box 8111
St. Louis, MO 63110
Lab: 314-747-7066; 314-294-1178

Procedures
The FACS study offers a comprehensive evaluation and collects data on a wide range of tests. WashU study coordinators schedule the tests in one continuous 4- to 5-day series to ease the burden of repeated travel and time off work. During this week, the family can obtain these procedures:

  • Blood draws to screen for known mutations causing AD.
  • Genetic counseling to learn about FAD and make an informed choice.
  • Clinical-grade genetic testing if the study participant chooses it after counseling.
  • Extensive cerebrospinal fluid (CSF) research. In addition to measuring a range of candidate biomarker proteins in CSF as done at other centers, this study offers a new technique developed at WashU and available only there. The study aims to measure how much of certain proteins a person's brain produces over time. The volunteer first receives an injection that labels the protein of interest, and then the neurologist inserts an epidural catheter like those used in childbirth anesthesia. The scientists take timed samples of spinal fluid for the next 36 hours, during which the volunteer is admitted to the hospital. This experiment aims to answer definitively a long-standing question in AD research, namely whether people with eFAD mutations get disease because their brain overproduces certain versions of the amyloid-β protein while underproducing other versions. Prior data in the blood, but not necessarily the brain, indicate as much, but it is either indirect or taken from single measurements that represent snapshots rather than continuous monitoring over a period of time. This part of the study is unique to WashU; interested families participating in studies elsewhere may want to ask their respective neurologist, or contact Dr. Bateman, to consider a referral for this study. All studies except for the 36-hour CSF study will be repeated at 3-year intervals after the first visit.
  • Blood draw for genetic analysis.
  • Two brain scans: MRI for structural data, PET-PIB imaging of amyloid deposition. No FDG PET, diffusion tensor imaging, MRS of brain metabolites at this time.
  • Clinical evaluation and neuropsychologic testing for early cognitive changes.
  • Memory and attention testing designed for participants younger than 60.

Family Support
The study arranges and pays for airfare and hotel for every volunteer plus an accompanying family member (e.g., spouse). The study offers some compensation for time off from work in that each major procedure pays out a separate stipend; inquire directly for details. Genetic counseling and, if requested, genetic testing are offered free of charge outside of health insurance. The study offers some follow-up after the study participants return home, and currently aims to obtain funding to support future visits. "Our goal is to build a structure that will enable the families to participate to the fullest extent that they wish. It is not just the right thing to do, but it is also important scientifically and medically," said Bateman. Interested families can contact Dr. Bateman to be put in touch with a family who is participating in this study and is willing to share its experience confidentially.


  Submit a Comment

 
Cast your vote and/or make a comment on this page. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Efad/EOAD Sidebars

How Early-onset Dementia Led to a Historic Discovery

Pushing the Envelope on Early Diagnosis

The Specter of Suicide

Taking the Plunge into Genetic Testing

Prevention With Statins: Can the Brain Learn From the Heart?

Efad/EOAD Interviewss

A Diagnostic Odyssey
NPR Interviews with Thomas Debaggio
A Courageous Family
Interview with Jennifer Williamson
One Man's Forward Approach
A Spouse's Perspective on Clinical Trials for eFAD
Q&A with Richard Bozanich
Interview with Lisa Genova

Early Onset AD Related Links

Actionalz.org Blog
AD Under 65 Message Board
Alzheimer Europe
Carved in Sand Blog
The Tangled Neuron
Early-Onset Issues
MayoClinic

Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad